Literature DB >> 25341587

Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian and primary peritoneal low-grade serous carcinomas.

Charlie Gourley1, John Farley, Diane M Provencher, Sandro Pignata, Linda Mileshkin, Philipp Harter, Johanna Maenpaa, Jae-Weon Kim, Eric Pujaide-Lauraine, Rosalind M Glasspool, Isabelle Ray-Coquard, David Gershenson.   

Abstract

Low-grade serous ovarian cancer is a recently described histological subtype of ovarian cancer that is clinically and molecularly distinct from the 4 other main histological subtypes (high-grade serous, clear cell, endometrioid, and mucinous). In particular, it differs from high-grade serous ovarian cancer in that it presents at a much younger age, is more indolent, and is relatively chemoresistant. Very few clinical trials have been performed exclusively in this tumor type; and as such, specific data guiding optimal management are limited.

Entities:  

Mesh:

Year:  2014        PMID: 25341587     DOI: 10.1097/IGC.0000000000000257

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  14 in total

1.  Differences in MEK inhibitor efficacy in molecularly characterized low-grade serous ovarian cancer cell lines.

Authors:  Marta Llauradó Fernández; Gabriel E DiMattia; Amy Dawson; Sylvia Bamford; Shawn Anderson; Bryan T Hennessy; Michael S Anglesio; Trevor G Shepherd; Clara Salamanca; Josh Hoenisch; Anna Tinker; David G Huntsman; Mark S Carey
Journal:  Am J Cancer Res       Date:  2016-10-01       Impact factor: 6.166

2.  Does the Presence of Endometriosis Affect Prognosis of Ovarian Cancer?

Authors:  Helen E Dinkelspiel; Cathleen Matrai; Sara Pauk; Alain Pierre-Louis; Ya-Lin Chiu; Divya Gupta; Thomas Caputo; Lora Hedrick Ellenson; Kevin Holcomb
Journal:  Cancer Invest       Date:  2016-03-17       Impact factor: 2.176

3.  Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup (GCIG): clinical trial design for rare ovarian tumours.

Authors:  A F Leary; M Quinn; K Fujiwara; R L Coleman; E Kohn; T Sugiyama; R Glasspool; I Ray-Coquard; N Colombo; M Bacon; A Zeimet; A Westermann; E Gomez-Garcia; D Provencher; S Welch; W Small; D Millan; A Okamoto; G Stuart; K Ochiai
Journal:  Ann Oncol       Date:  2017-04-01       Impact factor: 32.976

Review 4.  Secondary and tertiary ovarian cancer recurrence: what is the best management?

Authors:  Simone Garzon; Antonio Simone Laganà; Jvan Casarin; Ricciarda Raffaelli; Antonella Cromi; Massimo Franchi; Fabio Barra; Ibrahim Alkatout; Simone Ferrero; Fabio Ghezzi
Journal:  Gland Surg       Date:  2020-08

Review 5.  Epithelial ovarian cancer: the molecular genetics of epithelial ovarian cancer.

Authors:  J Krzystyniak; L Ceppi; D S Dizon; M J Birrer
Journal:  Ann Oncol       Date:  2016-04       Impact factor: 32.976

Review 6.  Ovarian cancer treatment: The end of empiricism?

Authors:  Stephanie Lheureux; Katherine Karakasis; Elise C Kohn; Amit M Oza
Journal:  Cancer       Date:  2015-06-10       Impact factor: 6.860

7.  Expression of hypothalamic-pituitary-gonadal axis-related hormone receptors in low-grade serous ovarian cancer (LGSC).

Authors:  Zheng Feng; Hao Wen; Xingzhu Ju; Rui Bi; Xiaojun Chen; Wentao Yang; Xiaohua Wu
Journal:  J Ovarian Res       Date:  2017-01-25       Impact factor: 4.234

8.  Testing for NRAS Mutations in Serous Borderline Ovarian Tumors and Low-Grade Serous Ovarian Carcinomas.

Authors:  Pawel Sadlecki; Dariusz Grzanka; Marek Grabiec
Journal:  Dis Markers       Date:  2018-02-25       Impact factor: 3.434

Review 9.  Targeting KRAS in Solid Tumors: Current Challenges and Future Opportunities of Novel KRAS Inhibitors.

Authors:  Alice Indini; Erika Rijavec; Michele Ghidini; Alessio Cortellini; Francesco Grossi
Journal:  Pharmaceutics       Date:  2021-05-04       Impact factor: 6.321

10.  Differential gene expression identifies a transcriptional regulatory network involving ER-alpha and PITX1 in invasive epithelial ovarian cancer.

Authors:  Yichao Li; Sushil K Jaiswal; Rupleen Kaur; Dana Alsaadi; Xiaoyu Liang; Frank Drews; Julie A DeLoia; Thomas Krivak; Hanna M Petrykowska; Valer Gotea; Lonnie Welch; Laura Elnitski
Journal:  BMC Cancer       Date:  2021-07-03       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.